Long‐term clinical outcomes of external beam radiation therapy for oligometastatic prostate cancer: A combination of prostate‐targeted treatment and metastasis‐directed therapy

2021 ◽  
Author(s):  
Rihito Aizawa ◽  
Kenji Takayama ◽  
Kiyonao Nakamura ◽  
Takashi Ogata ◽  
Takahiro Inoue ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Radiation Therapy ◽  
Clinical Outcomes ◽  
External Beam Radiation Therapy ◽  
Targeted Treatment ◽  
External Beam Radiation ◽  
External Beam ◽  
Beam Radiation ◽  
Oligometastatic Prostate Cancer

scholarly journals Long-term clinical outcomes of salvage pelvic radiation therapy for oligo-recurrent pelvic lymph nodes after definitive external-beam radiation therapy for non-metastatic prostate cancer

2020 ◽  
Vol 61 (4) ◽  
pp. 622-628
Author(s):  
Genki Edward Sato ◽  
Rihito Aizawa ◽  
Kiyonao Nakamura ◽  
Kenji Takayama ◽  
Takahiro Inoue ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Radiation Therapy ◽  
Lymph Nodes ◽  
External Beam Radiation Therapy ◽  
External Beam Radiation ◽  
External Beam ◽  
Beam Radiation ◽  
Pelvic Radiation ◽  
Pelvic Lymph Nodes

Abstract Although salvage external-beam radiation therapy (EBRT) is an attractive treatment option for pelvic lymph nodal recurrence (PeNR) in patients with prostate cancer (PCa), limited data are available regarding its long-term efficacy. This study examined the long-term clinical outcomes of patients who underwent salvage pelvic radiation therapy (sPRT) for oligo-recurrent pelvic lymph nodes after definitive EBRT for non-metastatic PCa. Patients who developed PeNR after definitive EBRT and were subsequently treated with sPRT at our institution between November 2007 and December 2015 were retrospectively analyzed. The prescribed dose was 45–50.4 Gy (1.8–2 Gy per fraction) to the upper pelvis, with up to 54–66 Gy (1.8–2 Gy per fraction) for recurrent nodes. Long-term hormonal therapy was used as neoadjuvant and/or adjuvant therapy. The study population consisted of 12 consecutive patients with PeNR after definitive EBRT (median age: 73 years). The median follow-up period was 58.9 months. The 5-year overall survival, PCa-specific survival, biochemical failure-free, clinical failure-free, and castration-resistant PCa-free rates were 82.5, 100.0, 62.3, 81.8, and 81.8%, respectively. No grade 2 or higher sPRT-related late toxicities occurred. In conclusion, more than half of the study patients treated with sPRT had a long-term disease-free status with acceptable morbidities. Moreover, most of the patients maintained hormonal sensitivity. Therefore, this approach may be a promising treatment method for oligo-recurrent pelvic lymph nodes.

Sign in / Sign up

Export Citation Format

Share Document